The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin
© Kvardova et al; licensee BioMed Central Ltd. 2010
Received: 11 March 2010
Accepted: 15 June 2010
Published: 15 June 2010
Cisplatin and its derivatives are commonly used anti-cancer drugs. However, cisplatin has clinical limitations including serious side effects and frequent emergence of intrinsic or acquired resistance. Thus, the novel platinum(IV) complex LA-12 represents a promising treatment modality, which shows increased intracellular penetration resulting in improved cytotoxicity in various cancer cell lines, including cisplatin resistant cells.
LA-12 disrupts cellular proliferation regardless of the p53 status in the cells, however the potency of the drug is greatly enhanced by the presence of a functional p53, indicating several mechanisms of action. Similarly to cisplatin, an interaction of LA-12 with molecular chaperone Hsp90 was proposed. Binding of LA-12 to Hsp90 was demonstrated by Hsp90 immunoprecipitation followed by platinum measurement using atomic absorption spectrometry (AAS). An inhibitory effect of LA-12 on Hsp90 chaperoning function was shown by decrease of Hsp90-assisted wild-type p53 binding to p21WAF1 promoter sequence in vitro and by accelerated ubiqutination and degradation of primarily unfolded mutant p53 proteins in cells exposed to LA-12.
To generalize our findings, LA-12 induced degradation of other Hsp90 client proteins such as Cyclin D1 and estrogen receptor was shown and proved as more efficient in comparison with cisplatin. This newly characterised molecular mechanism of action opens opportunities to design new cancer treatment strategy profitable from unique LA-12 properties, which combine DNA damaging and Hsp90 inhibitory effects.
Cisplatin [cis-diamminedichloroplatinum(II)] is a platinum-based anticancer drug commonly used for treatment of different types of cancer, including ovarian, testicular, head and neck or lung carcinomas . Although cisplatin exerts significant anti-tumour activity, cisplatin-based therapies cause numerous side effects, such as nephrotoxicity, neurotoxicity and nausea. The intrinsic as well as acquired resistances to cisplatin-based therapy also represent substantial complications for the treatment of tumours.
For this reason, vast efforts were committed to develop novel platinum-based complexes to overcome platinum resistance, to reduce cisplatin side effects and to introduce novel mechanisms of anti-cancer action. Two derivatives, carboplatin (cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II)) and oxaliplatin (trans-R,R.cyclohexane-1,2-diammine)oxalatoplatinum(II)), have been introduced . Taken together, these three drugs represent all of the available platinum drugs approved by the Food and Drug Administration for clinical use . In addition to substantial side effects, these three drugs also require intravenous administration, therefore a new generation of platinum drugs represented by satraplatin (JM216) [(OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV)] has been generated. JM216 represents the first orally administered platinum compound which has been evaluated in clinical trials [2, 4, 5].
LA-12, [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV)], is a hydrophobic platinum(IV) complex structurally similar to JM216, which contains 1-adamantylamine instead of cyclohexylamine non-leaving ligand  which provides this drug different properties. LA-12 has shown a higher cytotoxicity than JM216 when tested on a panel of 14 cancer cell lines of various origin and different cisplatin sensitivity [6, 7] and no cross-resistance with cisplatin [6, 8]. LA-12 has also displayed (i) higher antitumor activity in comparison with cisplatin and JM216, (ii) favourable pharmacokinetics and (iii) relatively low acute toxicity in a panel of pre-clinical in vivo studies [9–11].
The cytotoxic mode of action of cisplatin is mediated by its interaction with DNA to form DNA adducts, primarily intra-strand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis . JM216 has a mechanism of action similar to that of cisplatin, inducing the formation of DNA adducts and inter- and intra-strand crosslinks and resulting in G2 arrest and induction of apoptosis . The principle mechanisms of LA-12 effects are not fully understood to date, although there is some evidence that exposure to LA-12 can disrupt cell proliferation and induce apoptosis more potently than cisplatin in both p53 dependent and independent manners [14, 15]. Interestingly, LA-12 induces unique changes in the profile of gene expression compared to cisplatin, indicating a distinct mode of action resulting in the differential activation of both p53-dependent and p53-independent gene targets .
Besides the well known cisplatin DNA-mediated effect, the other mechanism of cisplatin action was described demonstrating that cisplatin may also disrupt the function of some proteins, including heat shock protein 90 (Hsp90) . According to this study, cisplatin associates with the molecular chaperone Hsp90 and reduces its' chaperone activity. For example, this can result in the degradation of steroid receptors  and/or inhibition of interaction between Hsp90 and inositol hexakisphosphate kinase-2 (IP6K2), which disrupts the inhibitory effect of Hsp90 on IP6K2, leading to increased diphosphoinositol pentakisphosphate (IP7) formation and sensitisation of cancer cells to apoptosis [19, 20].
Since it is supposed that LA-12 undergoes metabolic changes and serves actually as a pro-drug for chemotherapeutically active platinum analogues, it is possible that these active metabolites can interact with proteins analogous to cisplatin, resulting in stronger cytotoxic or cytostatic effects. According to this hypothesis we have analyzed whether LA-12 can bind to Hsp90 resulting in inhibition of its protective chaperoning function such as folding, stabilization, activation and assembly of its "client" proteins.
Time and dose dependent accumulation of LA-12 in cancer cells in comparison with cisplatin
LA-12 and cisplatin uptake into cells was determined by AAS platinum amount measurement in lysates of cells treated with different doses of these drugs for different periods of time. We observed rapid and high initial accumulation of platinum after 0.5 hour incubation with LA-12 in all concentrations used, rising up to 4 hours of incubation. In subsequent time points, platinum level remained stable. The platinum amount in cells was also dependent on the concentration used.
LA-12 specifically interacts with Hsp90
Analysis of interaction of Hsp90 with LA-12
Result (± SD)
ng Pt/mg protein
10 μM cisplatin
10 μM cisplatin
50 μM cisplatin
50 μM cisplatin
10 μM LA-12
10 μM LA-12
50 μM LA-12
50 μM LA-12
10 μM cisplatin
50 μM cisplatin
10 μM LA-12
50 μM LA-12
10 μM cisplatin
50 μM cisplatin
10 μM LA-12
50 μM LA-12
50 μM cisplatin
50 μM LA-12
50 μM cisplatin
50 μM LA-12
Inhibition of Hsp90 assisted p53 binding to promoter sequence of p21WAF1 by LA-12
LA-12 inhibits Hsp90 assisted folding and initiates degradation of unfolded proteins
Mechanism of mutant p53 protein degradation in response to LA-12
LA-12 induces degradation of not only mutant p53 but also of other Hsp90 client proteins
Importantly, the 10 μM drug dose used in our experiments is equal to 1.95 mg/l platinum, which corresponds to the plasma levels of platinum shown in previous in vivo studies [10, 24]. The maximum platinum plasma concentration 1.54 and 6.25 mg/l in rats was observed within 1 hour after oral administration of 38.6 and 540 mg/kg LA-12, respectively . Interestingly, maximum tolerated single oral dose of LA-12 in mouse model was 1000 mg/kg .
Platinum(IV) complexes represent a class of anticancer agents that are activated by reactions with reducing agents present in body liquids after their administration. Thus, the platinum(IV) complexes display potential advantages over their platinum(II) counterparts because of their greater stability and bioreductive activation, thereby allowing a greater proportion of the drug to arrive at the target intact. Thus, it is not surprising that the cellular uptake of LA-12 was faster and more effective than that of cisplatin (Figure 1).
Hsp90 is a molecular chaperone and is one of the most abundant proteins expressed in cells . Molecular chaperone Hsp90 is a member of the heat shock protein family, which is up-regulated in response to stress and its' in vivo function is ATP-dependent . Hsp90 exists as a homodimer, which contains three domains. The N-terminal domain contains an ATP-binding site that binds the natural products geldanamycin and radicicol. Hsp90 function depends upon the ability of the N-terminal domain to bind and hydrolyze ATP, which is regulated and coupled with the conformational changes of the Hsp90 dimer . The middle domain exhibits high affinity for co-chaperones as well as client proteins . The structure of the C-terminus of Hsp90 contains the MEEVD sequence, which is known to bind co-chaperones that contain multiple copies of the tetratricopeptide repeat (TPR), a 34 amino acid sequence . Interestingly, the middle C-terminal part of Hsp90 has been implicated biochemically as the site of a putative second cryptic ATP-binding site on Hsp90 . The contribution of this site to the overall regulation of chaperone function is not clear, but novobiocin has been reported to interact with this site and alter the conformation of the chaperone . Importantly, cisplatin has also been found to bind to an Hsp90 site that overlaps the putative ATP/novobiocin binding site in this region, leading to inhibition of some Hsp90 activities [17, 26]. The observed higher affinity of Hsp90 to LA-12 may be explained by very specific properties of C-terminal domain of Hsp90. This domain contains several solvent-exposed hydrophobic residues, which are responsible for binding of client protein such as unligated glucocorticoid receptor . Consequently the hydrophobic properties of LA-12 could explain its preferential binding to Hsp90 in contrast to cisplatin.
The ability of LA-12 to inhibit Hsp90 function was shown using several approaches. (i) EMSA, based on the fact that under physiological conditions the chaperone activity of Hsp90 is important for the transcriptional activity of genotypically wild-type p53  clearly demonstrated LA-12 as potent inhibitor of Hsp90 chaperoning function. (ii) Determination of p53 conformation in cells expressing various p53 mutants, which were exposed to LA-12, revealed that the unfolded mutant p53 proteins that do not rely on Hsp90 activity are less stable than folded mutant p53 proteins that require Hsp90 activity. These findings are in agreement with previous work showing that the half-life of p53 mutant positively correlates with their conformational stability .
It was shown that inhibition of Hsp90 results in ubiquitination and degradation of primarily unfolded p53 mutants. This MDM2-independent degradation of unfolded p53 mutant is mediated by chaperone interacting protein CHIP. Our results show that CHIP is responsible for LA-12 mediated degradation in the same way as 17-AAG, which supports our theories finding LA-12 as a specific Hsp90 inhibitor.
Accordingly to both higher cellular uptake of LA-12 and at least 10-fold higher presence of platinum bound to Hsp90 in cells exposed to LA-12 compared to cells treated by cisplatin (Table 1), a stronger suppressive effect of LA-12 on Hsp90 activity and function in relation to cisplatin could be expected. This statement was confirmed by the ability of LA-12 to influence the stability and degradation rate of other Hsp90 client proteins, such as estrogen receptor and cyclin D1 compared to cisplatin, which did not decrease the level of these proteins.
In summary, our data indicate that cellular uptake of LA-12 is more effective compared to cisplatin resulting in more extensive binding of LA-12 to Hsp90 in vivo. This interaction is responsible for direct inhibition of Hsp90 chaperone function. These unique properties predict LA-12 as a novel promising anti-cancer therapeutic exploiting dual mode of action in inducing genotoxic damage and inhibiting Hsp90 activity.
All human cancer cell lines were obtained from ATCC. Cell lines BT-474, MDA-MB-468, MDA-MB-231, T-47D, BT-549 and SK-BR-3 contain different p53 mutations (E285K, R273H, R280K, L194F, R249S and R175H, respectively), whereas the wild-type allele was lost in all these cell lines. MCF-7 cells contain wild-type p53, and H1299 cells are p53-null. Cells were periodically checked for morphology by microscope and regularly screened for mycoplasma using Hoechst staining.
Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen, Paisley, Scotland) supplemented with 10% fetal bovine serum (Invitrogen, Paisley, Scotland), 300 mg/l L-glutamine (Invitrogen, Paisley, Scotland), 100 U/ml penicillin (Invitrogen, Paisley, Scotland) and 0.1 mg/ml streptomycin (Invitrogen, Paisley, Scotland), in a humidified incubator at 37°C in 5% CO2 atmosphere. Cells were grown to 80% confluence prior to experimental treatments.
The following anti-neoplastic drugs were used in this study: LA-12, cisplatin (Pliva-Lachema a.s., Brno, Czech Republic), 17-AAG (Alexis Biochemicals, Lausen, Switzerland). LA-12 and cisplatin were dissolved in DMSO and diluted in cell medium to 0.5 mM stock solution and 17-AAG was dissolved in DMSO to 2 mM stock solution. Stock solutions of LA-12 and cisplatin were freshly prepared before use. The final concentration of DMSO in cell culture medium did not exceed 0.2%.
SDS-PAGE and western blotting
SDS-PAGE and western blotting were performed as described previously . The following antibodies were used: DO-1 mouse monoclonal antibody directed towards the epitope 20-SDLWKL-25 within the p53 N-terminal region , CM-1 rabbit polyclonal antibody against human p53 protein (in house antibody), CHIP-11.1 mouse monoclonal antibody recognizing full length as well as truncated CHIP protein (in house antibody), Estrogen Receptor (clone SP1) rabbit monoclonal antibody (Lab Vision, Fremont CA, USA), CD1 mouse monoclonal antibody recognizing Cyclin D1 (in house antibody), EEV1-2.1 mouse monoclonal antibody against Hsp90 protein (in house antibody) and AC-40 monoclonal antibody recognizing actin (Sigma-Aldrich Inc. St. Louis, USA), which was used as a protein loading control. Final concentration of all antibodies used for immunodetection of proteins was 1 μg/ml in 5% milk containing 0.1% Tween 20 in PBS.
Immunoprecipitation of conformationally different forms of p53 protein was performed using 1 μg of mouse monoclonal antibodies PAb1620 recognizing the wild-type conformation of human p53 protein at native form [33, 34] and PAb240 recognizing the mutant conformations of p53 at native form , as described previously [33, 35]. For immunoprecipitation of Hsp90 protein for platinum amount measurement by AAS, cells were lysed in 150 mM NaCl, 50 mM HEPES (pH 7.2) and 0.5% Tween 20 and sonicated. Protein concentrations were measured using Bradford's assay. 200 μl of cell lysate containing 400 μg of total protein was incubated overnight together with 2 μg of EEV2-1.1 mouse monoclonal antibody against Hsp90β protein (in house antibody) and AC88 mouse monoclonal antibody against Hsp90 protein (Stressgen Biotech Corp., Victoria, BC, Canada). 15 μl of G-protein sepharose beads (GE Healthcare, Wien, Austria) was used to precipitate the antibody. After three washes in lysis buffer, beads were resuspended in 200 μl of 150 mM NaCl, 50 mM HEPES (pH 7.2) and 0.5% Tween 20 and boiled for 10 min.
Preparation of samples for AAS platinum amount measurement
Cells were incubated for the given time intervals with different doses of LA-12 and cisplatin. Control and treated cells were collected by centrifugation, washed three times with ice-cold PBS, lysed in 150 mM NaCl, 50 mM HEPES (pH 7.2) and 0.5% Tween 20 and sonicated. Protein concentrations were measured using Bradford's assay. 200 μl of cell lysate were used for platinum amount measurement by AAS.
In vitro p53 DNA Binding Assay
Human wild-type p53 and human Hsp90β were purified and activity of p53 was quantified by EMSA as described previously . Simplified, the assay is based on the ability of human recombinant Hsp90 to restore the specific DNA binding activity of human recombinant p53 at 37°C in vitro. A preincubation with Hsp90 inhibitors prior to p53 inactivation at 37°C was carried out as described for geldanamycin .
List of abbreviations
Atomic absorption spectrometry
Electrophoretic mobility shift assay
Carboxy terminus of Hsp70-interacting protein
Mouse double minute 2 homolog
Heat shock protein 90
We thank Dr. P. J. Coates for critical reading of the manuscript. This work was supported by PLIVA-Lachema a. s., IGA MZ CR NS/9812-4, MZ0MOU2005 and GACR 301/08/1649.
- Ho YP, Au-Yeung SC, To KK: Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev. 2003, 23: 633-655. 10.1002/med.10038View ArticlePubMedGoogle Scholar
- Kozubik A, Vaculova A, Soucek K, Vondracek J, Turanek J, Hofmanova J: Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism. Met Based Drugs. 2008, 2008: 417-897. 10.1155/2008/417897.View ArticleGoogle Scholar
- Choy H, Park C, Yao M: Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res. 2008, 14: 1633-1638. 10.1158/1078-0432.CCR-07-2176View ArticlePubMedGoogle Scholar
- Fokkema E, Groen HJ, Bauer J, Uges DR, Weil C, Smith IE: Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol. 1999, 17: 3822-3827.PubMedGoogle Scholar
- Kelland LR: An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin Investig Drugs. 2000, 9: 1373-1382. 10.1517/135437126.96.36.1993View ArticlePubMedGoogle Scholar
- Zak F, Turanek J, Kroutil A, Sova P, Mistr A, Poulova A, Mikolin P, Zak Z, Kasna A, Zaluska D: Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J Med Chem. 2004, 47: 761-763. 10.1021/jm030858+View ArticlePubMedGoogle Scholar
- Turanek J, Kasna A, Zaluska D, Neca J, Kvardova V, Knotigova P, Horvath V, SI L, Kozubik A, Sova P: New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes. Anticancer Drugs. 2004, 15: 537-543. 10.1097/01.cad.0000127147.57796.e5View ArticlePubMedGoogle Scholar
- Horvath V, Blanarova O, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, Kroutil A, Fedorocko P, Kozubik A: Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecol Oncol. 2006, 102: 32-40. 10.1016/j.ygyno.2005.11.016View ArticlePubMedGoogle Scholar
- Cermanova J, Chladek J, Soval P, Kroutil A, Semerad M, Berankova Z, Siroky P, Surova I: Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs. Methods Find Exp Clin Pharmacol. 2004, 26: 679-685. 10.1358/mf.2004.26.9.872565View ArticlePubMedGoogle Scholar
- Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M: Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12. Anticancer Drugs. 2005, 16: 653-657. 10.1097/00001813-200507000-00010View ArticlePubMedGoogle Scholar
- Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M: Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts. Anticancer Drugs. 2006, 17: 201-206. 10.1097/00001813-200602000-00012View ArticlePubMedGoogle Scholar
- Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003, 22: 7265-7279. 10.1038/sj.onc.1206933View ArticlePubMedGoogle Scholar
- Mellish KJ, Barnard CF, Murrer BA, Kelland LR: DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer. 1995, 62: 717-723. 10.1002/ijc.2910620612View ArticlePubMedGoogle Scholar
- Horvath V, Soucek K, Svihalkova-Sindlerova L, Vondracek J, Blanarova O, Hofmanova J, Sova P, Kozubik A: Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin. Invest New Drugs. 2007, 25: 435-443. 10.1007/s10637-007-9062-7View ArticlePubMedGoogle Scholar
- Roubalova E, Kvardova V, Hrstka R, Borilova S, Michalova E, Dubska L, Muller P, Sova P, Vojtesek B: The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12. Invest New Drugs. 2010, 28 (4): 445-53. 10.1007/s10637-009-9270-4View ArticlePubMedGoogle Scholar
- Hrstka R, Powell DJ, Kvardova V, Roubalova E, Bourougaa K, Candeias MM, Sova P, Zak F, Fahraeus R, Vojtesek B: The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin. Anticancer Drugs. 2008, 19: 369-379. 10.1097/CAD.0b013e3282f7f500View ArticlePubMedGoogle Scholar
- Itoh H, Ogura M, Komatsuda A, Wakui H, Miura AB, Tashima Y: A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochem J. 1999, 343 (Pt 3): 697-703. 10.1042/0264-6021:3430697PubMed CentralView ArticlePubMedGoogle Scholar
- Rosenhagen MC, Soti C, Schmidt U, Wochnik GM, Hartl FU, Holsboer F, Young JC, Rein T: The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. Mol Endocrinol. 2003, 17: 1991-2001. 10.1210/me.2003-0141View ArticlePubMedGoogle Scholar
- Shames DS, Minna JD: IP6K2 is a client for HSP90 and a target for cancer therapeutics development. Proc Natl Acad Sci USA. 2008, 105: 1389-1390. 10.1073/pnas.0711993105PubMed CentralView ArticlePubMedGoogle Scholar
- Chakraborty A, Koldobskiy MA, Sixt KM, Juluri KR, Mustafa AK, Snowman AM, van Rossum DB, Patterson RL, Snyder SH: HSP90 regulates cell survival via inositol hexakisphosphate kinase-2. Proc Natl Acad Sci USA. 2008, 105: 1134-1139. 10.1073/pnas.0711168105PubMed CentralView ArticlePubMedGoogle Scholar
- Walerych D, Kudla G, Gutkowska M, Wawrzynow B, Muller L, King FW, Helwak A, Boros J, Zylicz A, Zylicz M: Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem. 2004, 279: 48836-48845. 10.1074/jbc.M407601200View ArticlePubMedGoogle Scholar
- Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B: Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene. 2008, 27: 3371-3383. 10.1038/sj.onc.1211010View ArticlePubMedGoogle Scholar
- Lukashchuk N, Vousden KH: Ubiquitination and degradation of mutant p53. Mol Cell Biol. 2007, 27: 8284-8295. 10.1128/MCB.00050-07PubMed CentralView ArticlePubMedGoogle Scholar
- Sova P, Chladek J, Zak F, Mistr A, Kroutil A, Semerad M, Slovak Z: Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)]. Int J Pharm. 2005, 288: 123-129. 10.1016/j.ijpharm.2004.09.020View ArticlePubMedGoogle Scholar
- Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G: The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther. 1998, 79: 129-168. 10.1016/S0163-7258(98)00013-8View ArticlePubMedGoogle Scholar
- Soti C, Racz A, Csermely P: A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem. 2002, 277: 7066-7075. 10.1074/jbc.M105568200View ArticlePubMedGoogle Scholar
- Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH: Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 1997, 90: 65-75. 10.1016/S0092-8674(00)80314-1View ArticlePubMedGoogle Scholar
- Hawle P, Siepmann M, Harst A, Siderius M, Reusch HP, Obermann WM: The middle domain of Hsp90 acts as a discriminator between different types of client proteins. Mol Cell Biol. 2006, 26: 8385-8395. 10.1128/MCB.02188-05PubMed CentralView ArticlePubMedGoogle Scholar
- Donnelly A, Blagg BS: Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem. 2008, 15: 2702-2717. 10.2174/092986708786242895PubMed CentralView ArticlePubMedGoogle Scholar
- Yun BG, Huang W, Leach N, Hartson SD, Matts RL: Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. Biochemistry. 2004, 43: 8217-8229. 10.1021/bi0497998View ArticlePubMedGoogle Scholar
- Fang L, Ricketson D, Getubig L, Darimont B: Unliganded and hormone-bound glucocorticoid receptors interact with distinct hydrophobic sites in the Hsp90 C-terminal domain. Proc Natl Acad Sci USA. 2006, 103: 18487-92. 10.1073/pnas.0609163103PubMed CentralView ArticlePubMedGoogle Scholar
- Vojtesek B, Bartek J, Midgley CA, Lane DP: An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods. 1992, 151: 237-244. 10.1016/0022-1759(92)90122-AView ArticlePubMedGoogle Scholar
- Milner J: Structures and functions of the tumor suppressor p53. Pathol Biol (Paris). 1997, 45: 797-803.Google Scholar
- Wang PL, Sait F, Winter G: The 'wildtype' conformation of p53: epitope mapping using hybrid proteins. Oncogene. 2001, 20: 2318-2324. 10.1038/sj.onc.1204316View ArticlePubMedGoogle Scholar
- Gannon JV, Greaves R, Iggo R, Lane DP: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. Embo J. 1990, 9: 1595-1602.PubMed CentralPubMedGoogle Scholar
- Walerych D, Olszewski MB, Gutkowska M, Helwak A, Zylicz M, Zylicz A: Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions. Oncogene. 2009, 28: 4284-4294. 10.1038/onc.2009.281View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.